Nusinersen versus sham control in later-onset spinal muscular atrophy
<p><strong>Background:</strong><br /> Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA).</p><br /> <p&g...
Main Authors: | Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, Iannaccone, ST, Kirschner, J, Kuntz, NL, Saito, K, Shieh, PB, Tulinius, M, Mazzone, ES, Montes, J, Bishop, KM, Yang, Q, Foster, R, Gheuens, S, Bennett, CF, Farwell, W, Schneider, E, De Vivo, DC, Finkel, RS |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Massachusetts Medical Society
2018
|
Similar Items
-
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
by: Finkel, RS, et al.
Published: (2017) -
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
by: Aragon-Gawinska, K, et al.
Published: (2019) -
Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
by: Gidaro, T, et al.
Published: (2018) -
RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy - rationale and study design
by: Finkel, RS, et al.
Published: (2020) -
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study
by: Aragon-Gawinska, K, et al.
Published: (2018)